A Singaporean healthtech leader that has created a tech solution to connect cancer patients, hospitals and industry in real time will establish its Australian headquarters in Melbourne.
Oncoshot’s technology helps oncologists identify cancer clinical trials more efficiently and effectively for patients and their caregivers by supporting hospitals and research partners.
Built on data and insights, the company’s focus is to leverage AI technology to address the inefficiencies of cancer clinical trials. The platform will support the deployment of relevant and innovative clinical trials for patients across public and private cancer institutes in Australia when fully deployed.
Oncoshot Chief Executive, Huren Sivaraj said, “Victoria was an ideal partner to support Oncoshot’s growth within Australia with its ecosystem of leading cancer hospitals and talent pool of highly skilled clinicians, researchers and technical talents.”
Oncoshot has signed its first Australian partner, Omico, which is one of the country’s leading cancer research networks. This partnership will create opportunities for patients in Omico’s network of hospitals across Australia to participate in global trials.
Founded in 2018 by Dr Huren Sivaraj, a medical oncologist, and Ruslan Enikeev, a data science engineer, Oncoshot’s data system was designed to analyse large amounts of data across healthcare institutions and regional and national borders while observing data protection regulations.
Victoria is the nation’s leading hub for health and medical research, consistently receiving more than 40 per cent of Commonwealth Government funding from the National Health and Medical Research Council (NHMRC). The sector supports more than 30,000 jobs across institutes, universities and industry.
Read more about opportunities in Victoria’s digital health sector.
To explore available investment opportunities, contact our team.
